Abstract

One major hallmark of atopic dermatitis (AD) is the elevated level of total serum IgE, which has been reported to be partly of the autoreactive type in a subset of patients. Immunoadsorption (IA) has been successfully applied in various classical autoantibody-mediated diseases such as pemphigus. Recent reports proposed the use of IA also for patients with severe AD and high total serum IgE levels. In this mini-review, we summarize the current knowledge about this novel treatment approach for AD and briefly discuss the so far incompletely known role of autoreactive IgE as potential target of IA therapy in this common inflammatory skin disorder.

Highlights

  • Targeting ige Antibodies by immunoadsorption in Atopic DermatitisMichael Kasperkiewicz1*, Enno Schmidt[1,2], Ralf J

  • Atopic dermatitis (AD) is a chronic or chronically relapsing, eczematous, pruritic skin disease affecting 2–20% of the general population, which can considerably affect the patient’s quality of life

  • We reported two cases of S. aureus septicemia, one occurring after panimmunoglobulin IA and the other following IgE-selective IA, both performed by a central venous catheter (4, 9)

Read more

Summary

Targeting ige Antibodies by immunoadsorption in Atopic Dermatitis

Michael Kasperkiewicz1*, Enno Schmidt[1,2], Ralf J. Targeting IgE Antibodies by Immunoadsorption in Atopic Dermatitis. One major hallmark of atopic dermatitis (AD) is the elevated level of total serum IgE, which has been reported to be partly of the autoreactive type in a subset of patients. Immunoadsorption (IA) has been successfully applied in various classical autoantibody-mediated diseases such as pemphigus. Recent reports proposed the use of IA for patients with severe AD and high total serum IgE levels. In this mini-review, we summarize the current knowledge about this novel treatment approach for AD and briefly discuss the so far incompletely known role of autoreactive IgE as potential target of IA therapy in this common inflammatory skin disorder

INTRODUCTION
IA Protocols
Effects on the Clinical Course
Effects on Circulating IgE and Other Serum Parameters
Side effects
Mean SCORAD improvement by Temporal mean serum IgE
Autoreactive IgE as Potential Target of IA in AD
Findings
CONCLUSION

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.